Continuing Education Activity

Lymphedema is a chronic condition characterized by swelling, typically in the limbs, resulting from impaired lymphatic drainage. This condition most commonly occurs after cancer treatment, particularly when lymph nodes are removed or irradiated, but it can also arise from infections, injuries, or congenital abnormalities. Risk factors include obesity, limited mobility, and recurrent infections. Management focuses on early recognition, infection prevention, meticulous skin care, exercise, weight management, and compression garments. Effective care relies on patient education, self-management techniques such as manual lymphatic drainage, and a multidisciplinary approach involving clinicians, certified lymphedema therapists, nurses, physical and occupational therapists, pharmacists, and mental health professionals to address physical and psychosocial needs.

Clinicians participating in this course can expect a comprehensive understanding of the pathophysiology, risk factors, and clinical presentation of lymphedema, along with evidence-based strategies for prevention, early detection, and management. They learn how to implement patient-centered interventions, coordinate care within an interprofessional team, and provide education to empower patients in self-care. Additionally, the course emphasizes recognizing complications, optimizing adherence to therapy, and addressing the psychosocial impacts of lymphedema, ultimately equipping clinicians to improve patient outcomes, enhance safety, and foster long-term quality of life for individuals with this condition.

Objectives:

• Identify the pathophysiology of lymphedema, including lymphatic dysfunction and tissue remodeling.
• Evaluate the clinical presentation of lymphedema, including anatomical distribution, staging criteria, early versus advanced signs, and diagnostic distinctions from other causes of edema.
• Implement evidence-based and emerging treatment strategies, such as complete decongestive therapy, surgical approaches, compression therapy, and novel lymphangiogenic interventions.
• Communicate the importance of interdisciplinary care coordination, including early referral to certified lymphedema specialists and collaborative management involving clinicians, nurses, therapists, and patient education strategies to optimize outcomes.

Introduction

The lymphatic system consists of initial capillaries, collecting vessels, trunks, and lymph nodes that transport lymph, a fluid rich in proteins, immune cells, lipids, and metabolic waste. Superficial and deep lymphatic networks are connected by perforating vessels that traverse fascial layers, maintaining tissue fluid balance and immune surveillance.[1] Lymphedema is a chronic, progressive condition caused by impaired lymphatic drainage, leading to the abnormal accumulation of protein-rich lymphatic fluid in the interstitial tissues. When lymphatic transport capacity is exceeded, persistent edema triggers inflammation and progressive tissue remodeling, resulting in functional decline and long-term morbidity.[2]

Lymphedema is classified as primary, due to congenital or genetic abnormalities in lymphatic development, or secondary, arising from acquired injury or obstruction. Secondary causes include surgery, radiation therapy, infection, trauma, and malignancy, with limb involvement most often seen following oncologic treatment.[3][4] Although extremities are most commonly affected, the head and neck, trunk, or genitalia can also be involved, leading to cosmetic deformity, psychological distress, and impaired function.[3] Clinically, patients present with swelling, heaviness, discomfort, reduced mobility, skin thickening, and difficulty wearing clothing. Complications such as recurrent infections and progressive decline in quality of life frequently occur without timely intervention.[4]

Etiology

Lymphedema develops when lymphatic drainage is disrupted, causing progressive accumulation of protein-rich interstitial fluid, chronic inflammation, and soft tissue remodeling. This condition is classified as primary, resulting from congenital or genetic lymphatic abnormalities, or secondary, due to acquired lymphatic injury or obstruction. Although the true prevalence of inherited primary lymphedema is uncertain, estimates vary widely.[5]

Primary Lymphedema

This rare form arises from developmental malformations such as lymphatic hypoplasia, aplasia, or hyperplasia, which may occur in isolation or within syndromic disorders.[6][7][8] This type is further categorized by age of onset: congenital (birth/infancy), praecox (puberty to early adulthood, as in Meige disease and representing ~94% of cases), and tarda (onset after age 35).[6][7] Mutations in genes including FLT4 (vascular endothelial growth factor receptor 3 [VEGF]) and FOXC2 disrupt lymphangiogenesis and underlie many familial cases. Syndromic causes include Turner, Noonan, Klippel-Trénaunay-Weber, and Hennekam lymphangiectasia–lymphedema syndromes.[7] Turner syndrome commonly presents with neonatal pedal edema, with severity linked to specific karyotype abnormalities.[6][7] Hennekam syndrome, an autosomal recessive lymphatic dysplasia caused by CCBE1 or FAT4 mutations, manifests with intestinal and pulmonary lymphangiectasia and may include recurrent pericardial effusions, highlighting its systemic nature.[7]

Secondary Lymphedema

Far more common, secondary lymphedema results from acquired lymphatic injury, obstruction, or overload.[9] Worldwide, lymphatic filariasis (Wuchereria bancrofti) remains the leading cause in tropical and subtropical regions. In developed countries, cancer therapy–related lymphedema predominates, typically after lymph node dissection, radiation, or tumor infiltration.[8][9] High-risk malignancies include breast, gynecologic, genitourinary, and head and neck cancers; a meta-analysis found lymphedema rates up to 90% after multimodal head and neck cancer treatment with radiation and extensive nodal dissection.[10][11]

Axillary web syndrome (AWS), palpable cord-like axillary bands after lymphadenectomy, significantly increases the risk of breast cancer–related lymphedema. A 2024 meta-analysis demonstrated higher lymphedema incidence in patients with AWS, reflecting shared mechanisms of lymphatic disruption and inflammation. Lymph node dissection and adjuvant radiation act independently and synergistically to impair lymphatic drainage.[12]

Risk factors for cancer-related lymphedema include the extent of surgery, radiation dose, high body mass index (BMI), infection history, and medical comorbidities. Preventive strategies such as sentinel lymph node biopsy and emerging microsurgical techniques can reduce lymphatic injury.[13] Other nononcologic causes include trauma, chronic venous insufficiency, inflammatory skin disease, and obesity. The Lymphedema Impact and Prevalence International (LIMPRINT) study confirmed a strong link between elevated BMI and chronic lower-limb edema, with higher BMI correlating with more severe disease and functional decline.[14]

Epidemiology

Lymphedema is a major but underrecognized global health challenge, affecting an estimated 140 to 250 million people worldwide. Reliable incidence data remain limited because of underdiagnosis, nonstandardized diagnostic criteria, and inconsistent terminology across clinical settings. In breast cancer survivors alone, 6% to 30% develop clinically significant arm lymphedema after axillary surgery despite advances in surgical and radiation techniques.[4]

Primary Lymphedema

Primary lymphedema is rare, affecting about 1 in 100,000 individuals and representing less than 10% of cases in the United States.[3][4] This type typically presents in adolescence or early adulthood and may occur sporadically or within familial clusters.[3][4] Congenital lymphedema, as seen in Turner syndrome, can manifest in infancy.[6]

Secondary Lymphedema

Accounting for more than 90% of global cases, secondary lymphedema results from acquired lymphatic injury or obstruction.[11] In the United States, recent estimates suggest 8 to 10 million affected individuals—roughly 3% of the population—a marked rise from older estimates of 1 in 1000.[11] Worldwide, lymphatic filariasis remains the leading cause in tropical and subtropical regions, whereas in high-income countries, cancer therapy is the predominant etiology. Incidence varies by cancer type, treatment modality, and the extent of lymphatic disruption.[5][7]

Cancer-Related Lymphedema

Population-based data show the highest lymphedema rates following gynecologic, breast, and genitourinary cancers, emphasizing the need for disease-specific surveillance. Among breast cancer survivors, 10% to 40% develop lymphedema, with risk highest after axillary lymph node dissection and radiation compared with sentinel lymph node biopsy alone. Gynecologic cancer patients undergoing pelvic lymphadenectomy and radiation face a 20% to 40% risk, with some series reporting up to 37% incidence in the first year posttreatment.[7] Head and neck cancer patients treated with multimodality therapy experience lymphedema rates as high as 90%, often involving the face, neck, and intraoral tissues.[15]

Sex-Based Differences and Population Trends

Men more often develop lymphedema from trauma, infection, or chronic venous disease, whereas women are more commonly affected by cancer therapy–related lymphedema, suggesting sex-specific etiologic patterns. A nationwide South Korean analysis using the Health Insurance Review and Assessment (HIRA) database demonstrated a rising incidence of lymphedema and notable demographic variation by age and sex, highlighting its growing healthcare burden.[16]

Pathophysiology

Lymphedema is a form of low-output lymphatic failure, in which the lymphatic system's transport capacity is insufficient de

spite normal capillary filtration. This distinguishes it from high-output edemas, such as those seen in cardiac or renal disease, where lymphatics are overwhelmed by excess fluid production.[2] 

Inflammation and Fibrosis

Impaired lymph clearance initiates a chronic inflammatory cascade. Interstitial stasis attracts CD4 T cells—particularly Th2 subtypes—and macrophages, which release profibrotic cytokines including interleukin (IL)-4, IL-13, and tumor growth factor (TGF)-β1. These mediators drive fibroblast activation and extracellular matrix accumulation, leading to progressive tissue fibrosis.[17][18] Chronic inflammation compromises immune surveillance, increasing susceptibility to recurrent infections such as cellulitis and erysipelas.

Adipose Tissue Remodeling

Lymphedema is characterized not only by fibrosis but also by abnormal adipose deposition. Proinflammatory signaling promotes adipocyte hypertrophy and expansion, contributing to structural remodeling. Transcriptional changes linked to adipogenesis further perpetuate lymphatic dysfunction and tissue stiffness.[19]

Lymphatic Pump Failure and Biomechanics

Structural and functional damage to collecting lymphatic vessels, including valvular incompetence and smooth muscle dysfunction, impairs active lymph propulsion. These biomechanical failures contribute to fluid stagnation and progressive edema.[20] Lymphatic endothelial dysfunction also disrupts immune cell trafficking and antigen presentation, exacerbating local immune dysregulation.[21]

Complications and Rare Sequelae

Persistent immune suppression and tissue remodeling predispose patients to recurrent soft tissue infections. In rare, long-standing cases, lymphedema may progress to lymphangiosarcoma (Stewart-Treves syndrome), with an estimated incidence of 0.45% in postmastectomy patients and a poor prognosis.[22]

Molecular and Experimental Insights

Animal models have replicated key features of human lymphedema, such as fibrosis, immune cell infiltration, and lymphatic remodeling. Recent studies have identified fibroblast subtypes associated with extracellular matrix changes and disease progression, offering potential therapeutic targets.[23] At the molecular level, chronic lymphedema is linked to sustained activation of the VEGF-C/VEGF receptor-3, TGF-β, and nuclear factor kappa-light-chain-enhancer of activated B cells pathways, reinforcing its classification as a fibroinflammatory disease.[24]

Skin and Tissue Alterations

Breast cancer–related lymphedema has been associated with skin barrier defects, including impaired epidermal differentiation and tight junction dysfunction, which exacerbate inflammation and infection risk.[25] Multi-omics analyses have further revealed metabolic and structural changes in affected adipose tissue, reinforcing the systemic impact of chronic lymphatic failure.[26]

Emerging Therapeutic Mechanisms

Targeted therapies aimed at modifying fibrotic remodeling are under investigation. Inhibition of uPARAP, a key regulator of extracellular matrix turnover, has shown promise in preclinical models by improving lymphatic architecture and reducing disease burden.[27] Device-based adjuncts, such as mechanical lymphatic stimulators, are also being evaluated for patients unresponsive to standard care, with early studies reporting favorable safety profiles. Gene therapy approaches, such as adenoviral delivery of VEGF-C, and cell-based therapies are being studied for their potential to promote lymphangiogenesis, although these remain investigational.[28]

Differentiation from Lipedema

Although often coexisting, lipedema is a distinct entity characterized by symmetric adipose tissue deposition with minimal lymphatic compromise in early stages. Unlike lymphedema, it typically spares the feet and presents without significant pitting edema.[29][30]

Conclusion

The lymphatic system plays a critical role in fluid homeostasis and immune regulation. Disruption of its structure and function results in persistent inflammation, immune dysregulation, and irreversible tissue remodeling. 

Histopathology

There is no single pathognomonic histologic feature of lymphedema; however, findings vary by disease stage and reflect its underlying fibroinflammatory pathogenesis.

Early-Stage Changes

Early lymphedema is marked by:

• Dermal edema, with expansion of the interstitial space due to protein-rich lymphatic fluid
• Dilated lymphatic vessels in the dermis and subcutis
• Minimal fibrosis, with limited inflammatory infiltrates [31]

Chronic-Stage Changes

With chronicity, histologic changes become more pronounced:

• Epidermal hyperplasia occurs, including hyperkeratosis, acanthosis, and papillomatosis with wart-like projections.
• Dermal fibrosis is characterized by thickened collagen bundles and increased fibroblast density, particularly in the upper dermis.[32]
• Vascular changes are evident, including telangiectatic blood vessels with thickened walls.
• Perilymphatic fibrosis develops, with disorganized extracellular matrix deposition around lymphatics and adipocytes.
• Adipose expansion occurs in longstanding disease and is characterized by adipocyte hypertrophy and subcutaneous fat accumulation.

Immunologic and Molecular Findings

Immunohistochemical analyses and murine models have revealed chronic infiltration by CD4 T lymphocytes and M2-polarized macrophages, localized near lymphatics and fibrotic regions.[33]These immune cells secrete Th2-associated cytokines such as IL-4, IL-13, and TGF-β1, driving fibrosis and adipogenesis.[5][34][35] In some cases, lymphatic endothelial hyperplasia may also be observed, though vessel function typically declines over time.

Imaging-Histology Correlation

Ultrasound and other imaging modalities often mirror histologic changes. Increased echogenicity reflects dermal fibrosis, while echo-free spaces correspond to interstitial fluid accumulation in the subcutaneous layer.[36]

Diagnostic Considerations

Histologic findings support the clinical assessment and correlate with disease progression. Thus, accurate evaluation begins with a thorough patient history and physical examination.

History and Physical

Accurate diagnosis of lymphedema requires a combination of clinical history, physical examination, objective measurements, and, when indicated, imaging. Early identification is essential to prevent irreversible fibroadipose tissue remodeling, functional decline, and complications like recurrent cellulitis.

History

A detailed history can help distinguish primary from secondary lymphedema:

• Onset and duration

  • Gradual or sudden onset; latency from triggering events
• Family history

  • Relevant for primary lymphedema, which may follow autosomal dominant inheritance with incomplete penetrance [3]
• Cancer history

  • Especially breast, melanoma, pelvic, and head and neck cancers with surgery or radiation
• Surgical/traumatic injury

  • Includes lymphadenectomy, orthopedic procedures, or burns
• Recurrent infections

  • Episodes of cellulitis or erysipelas
• Foreign travel

  • Exposure to filariasis-endemic regions
• Comorbidities

  • Congestive heart failure, renal or hepatic disease, hypothyroidism (can contribute to generalized edema)
• Symptoms

  • Heaviness, tightness, restricted motion; “pain is generally mild unless secondary infection, such as cellulitis, is present”

Physical Examination

Lymphedema typically presents as chronic, asymmetric swelling beginning distally. Key findings include:

• Stemmer sign

  • Inability to pinch the skin at the base of the second toe or finger (pathognomonic) [37]
• Edema pattern

  • Pitting in early stages; becomes nonpitting as fibrosis advances
• Skin changes

  • Hyperkeratosis, papillomatosis, lymphangiomas, peau d’orange
• Distribution clues

  • Primary lymphedema often involves the feet (lipedema spares them)
• Syndromic features

  • Webbed neck (Turner), port-wine stains (Klippel-Trénaunay), hypoplastic nails
• Functional impact

  • Reduced joint range, gait changes, and impaired activities of daily living in advanced disease

Evaluation

Quantitative Assessment

Objective tools enhance diagnostic accuracy and longitudinal tracking.[38] They include: 

• Circumferential measurements

  • Measurements of ≥2 cm or ≥200 mL volume difference between limbs are significant.
• Volume estimation 

  • This is achieved via truncated cone formulas, perometry, or 3-dimensional (3D) infrared scanning.
• Bioimpedance spectroscopy (BIS)

  • BIS detects extracellular fluid shifts. An L-Dex change >6.5 to 7.5 units indicates subclinical lymphedema.[39][40][41]
  • BIS enables early detection and risk stratification, improving long-term outcomes.[42] 
  • Some centers have adopted preoperative BIS measurements to establish fluid baselines in cancer patients before lymphadenectomy, improving early detection of subclinical changes.[43][44]

Imaging Modalities

Imaging supports diagnosis in uncertain cases and surgical planning.[45] They include:

• Duplex ultrasonography

  • Excludes deep vein thrombosis; differentiates venous causes
• Lymphoscintigraphy

  • Functional gold standard showing dermal backflow and delayed tracer clearance
• Indocyanine green (ICG) lymphography

  • Real-time mapping of superficial lymphatics [46][47]
• Magnetic resonance lymphangiography (MRL)

  • Visualizes deep lymphatic channels and soft tissue changes [39]
• Contrast-enhanced ultrasound (CEUS) fusion

  • Combines with magnetic resonance imaging (MRI) and computed tomography (CT) to aid microsurgical targeting
• Multimodal imaging

  • Combinations (eg, ICG + MRL) improve diagnostic clarity in complex cases.[48]

Special Considerations

• Head and neck lymphedema (HNL)

  • Subtle early signs make diagnosis challenging.
  • Near-infrared fluorescence lymphography and high-frequency ultrasound improve detection.
  • A 2025 Delphi study noted global variability in HNL criteria, underscoring the need for standardization.[49]
• Genital and lower abdominal lymphedema

  • Often underrecognized, symptoms like fullness or pressure may precede swelling.
• Emerging diagnostics

  • Artificial intelligence (AI)-driven image analysis, biosensors, and elastography are being investigated to detect early or subclinical disease.
• Risk stratification

  • Validated models and nomograms now guide surveillance strategies in high-risk populations (eg, postcancer surgery).

Treatment / Management

Lymphedema is chronic and progressive, requiring a multimodal approach. While curative options are limited, early and individualized treatment significantly improves outcomes.[50]

Conservative (Nonsurgical) Management

The primary therapeutic strategy for managing lymphedema is complex decongestive therapy (CDT), which is typically delivered in 2 phases.[51][52]

• Phase I (intensive phase) includes MLD, multilayer compression bandaging, skin care, and decongestive exercises.[53][54][55]
• Phase II (maintenance phase) focuses on long-term self-management through continued use of compression garments, exercise, skin hygiene, and self-administered MLD.[56][57]

Originally developed and refined in Europe and later introduced to the United States in the early 1990s, CDT remains the primary treatment approach for stage II and III lymphedema. The effectiveness of this treatment has been widely demonstrated across clinical settings worldwide. Recent study results confirm that CDT reduces limb volume and improves functional status.[52][58] Additional conservative strategies include:

• Compression therapy:

  • This is essential at all stages.[59] Adjustable wraps offer better adherence for some patients.[60]
• Exercise

  • Supervised resistance training improves limb function without increasing lymphedema risk.[20][21][61][62]
• Pneumatic compression devices

  • This serves as an adjunct during the maintenance phase.
• Adjunctive therapies

  • Low-level laser therapy and Kinesio taping may offer mild symptom relief.[53]
• Filariasis-related care

  • In endemic regions, treatment includes antifilarial drugs such as diethylcarbamazine or ivermectin, hygiene, compression, and exercise, often delivered via community programs.[59]

Medical Management

Supportive medical therapy includes:

• Antibiotics

  • For cellulitis prevention and treatment
• Topical agents

  • Keratolytics (eg, urea) or tacrolimus for papillomatosis
• Analgesics

  • For discomfort flares
• Prophylactic compression

  • Increasingly used immediately post-lymphadenectomy to prevent progression

Recent expert consensus supports its use as part of early risk-reduction strategies in high-risk patients, particularly following breast cancer surgery. Although the Food and Drug Administration has not approved any pharmacologic agents for lymphedema, investigational therapies such as ketoprofen have demonstrated anti-inflammatory effects and potential volume reduction in small trials. These agents target pathways like leukotriene signaling and oxidative stress and may offer future adjunctive options.

Surgical Management

The goal of excisional treatment of lymphedema is to remove the deposited fibrofatty tissue using either liposuction or resection. Liposuction is particularly effective in the upper extremity and has few adverse effects. Individuals with lymphedema treated with liposuction have a substantial long-term decrease in limb volume and improved quality of life when used alongside compression garments.

Radical resection is a treatment option used only after failure of other treatments, and is much more likely to result in substantial morbidity due to the increased level of invasiveness. Surgical options are reserved for refractory or advanced disease and include:

• Lymphovenous anastomosis (LVA) and lymphaticovenous bypass (LVB)

  • Microsurgical diversion of lymph into venous circulation [26]
• Vascularized lymph node transfer (VLNT)

  • Autologous transfer of lymph node–bearing tissue to reestablish drainage [63][64]
• Suction-assisted protein lipectomy (SAPL)

  • Liposuction-based removal of fibroadipose tissue in chronic lymphedema [65]
• Preventive LVA, such as the lymphatic microsurgical preventive healing approach (LYMPHA)

  • Involves immediate lymphatic reconstruction during cancer surgery and has been shown to reduce the incidence of lymphedema.[52][65][66][67]
• Sentinel lymph node biopsy

  • This is now preferred over full dissection to reduce risk.
• Advanced technologies

  • Super microsurgery, robotic assistance, and near-infrared imaging enhance surgical precision and accessibility.

Patient-Specific Strategies and Surgical Innovations

• Breast cancer–related lymphedema

  • Management includes CDT, compression, LYMPHA during axillary surgery, and survivorship education.[68][69][70][71]
• HNL

  • Requires tailored therapy including compression garments and, in select cases, LVA or VLNT [61]
• Elective surgery on affected limbs

  • May proceed with precautions (eg, infection prophylaxis, minimal tourniquet use)
• Precision care

  • Advanced imaging, wearable sensors, and patient-specific physiotherapy regimens support a shift toward personalized, survivorship-centered management.

Evidence-Based Practice and Long-Term Outcomes

Key best practices to optimize lymphedema outcomes include the following:

• Surveillance and early detection

  • High-risk individuals, such as those postmastectomy, should be monitored regularly using tools like BIS or perometry. Early identification enables timely intervention before significant edema develops.[72][73]
• Tailored compression

  • Compression therapy must be individualized. Proper fitting and routine reassessment are crucial as limb size and shape change.
• Adjunct therapies

  • Some patients benefit from additional modalities such as kinesiotaping, low-level laser therapy, myofascial release, or pneumatic compression. These can be integrated into care plans on a case-by-case basis.
• Adherence support

  • Ongoing education, psychosocial support, and regular follow-up improve long-term adherence to compression and self-care.[71]
• Postoperative care

  • For those undergoing lymphedema surgery, coordinated postop management (compression, physical therapy, psychosocial support) is vital to optimize outcomes and prevent relapse.

Differential Diagnosis

Lymphedema must be distinguished from other causes of localized or generalized edema. A systematic approach includes evaluating systemic and local/regional conditions with overlapping clinical presentations.

Differential Diagnosis of Lower Extremity Edema 

• Lipedema

  • Lipodystrophy, most common in obese women
  • Causes symmetrical enlargement of calves and thighs
  • Feet spared, unlike lymphedema
  • May show pitting edema
• Venous insufficiency

  • Hydrostatic cause of leg edema
  • Associated with cutaneous changes, such as hemosiderin deposits
  • Role determined by history and clinical context
• Lymphatic–venous interaction

  • Venous hypertension can increase lymphatic load, causing secondary lymphedema.
  • Many patients present with mixed lymphatic–venous edema.
  • This is also known as “phlebolymphedema.”

Systemic Causes

• Congestive heart failure
• Nephrotic syndrome or glomerulonephritis
• Hepatic cirrhosis with anasarca
• Hypoproteinemia, including that from severe malnutrition
• Drug-induced edema (eg, calcium channel blockers)
• Thyroid disease, especially Graves' disease with pretibial myxedema
• Constrictive pericarditis

Local/Regional Causes

• Deep vein thrombosis: Acute, often unilateral swelling
• Chronic venous insufficiency: Stasis edema with hemosiderin skin changes
• Lipedema: Symmetric adipose accumulation in the lower extremities, sparing the feet; minimal pitting [74]
• Baker cyst: Posterior knee mass with referred calf swelling
• Dependency edema: Improves with limb elevation
• Cellulitis: Painful, erythematous edema with systemic signs
• Malignancy: Tumor-related obstruction of lymphatics or veins
• Postsurgical edema: Transient, resolves with healing
• Arthritis-related joint swelling: May involve adjacent soft tissues

Key Distinguishing Features

Important clinical clues include:

• Laterality

  • Lymphedema is often unilateral; lipedema and systemic edema are typically bilateral.
• Pitting

  • Lymphedema begins with pitting, which resolves as fibrosis progresses. Lipedema shows little to no pitting early.
• Foot involvement

  • Lymphedema affects the feet; lipedema spares them.
• Response to elevation or diuretics

  • Lymphedema is less responsive than venous or dependent edema.
• Skin findings

  • Hyperkeratosis and papillomatosis in lymphedema; stasis dermatitis in venous disease.
• Imaging

  • Duplex ultrasound, lymphoscintigraphy, and MRI aid differentiation.

In rare cases, inherited lymphatic syndromes (eg, Hennekam lymphangiectasia–lymedema syndrome) present with limb swelling and associated organ involvement, such as intestinal lymphangiectasia or pleural/pericardial effusions. These require broader systemic evaluation. Lipedema is frequently misdiagnosed as lymphedema. This condition presents with symmetrical lower limb fat deposition sparing the feet, minimal early pitting, and typically no history of infection or skin changes. Lipedema is often associated with pain or tenderness and predominantly affects women.[29][75][76] HNL may be mistaken for other causes of facial or cervical swelling and often presents with subtle or atypical features. This type requires specialized evaluation techniques and clinician awareness to avoid misdiagnosis.[49]

Staging

Staging of Lymphedema

The International Society of Lymphology (ISL) classifies lymphedema into 4 clinical stages that reflect the chronicity and progression of lymphatic dysfunction. Accurate staging is essential for guiding treatment and prognosis.

• Stage 0 (latency/subclinical stage)

  • Lymphatic transport is impaired, but no visible or palpable edema is present.
  • The limb is “at risk,” particularly after lymph node dissection or radiation.
  • Imaging such as lymphoscintigraphy or ICG lymphography may detect reduced lymphatic flow.[4][46][77][78]
  • This stage may persist for months or years without clinical progression.
• Stage I (spontaneously reversible lymphedema)

  • Marked by soft, pitting edema that often develops throughout the day and typically subsides with limb elevation or overnight.
  • Fibrosis is minimal or absent.
  • Swelling usually begins distally (eg, hand or foot) and may fluctuate.
  • Conservative therapy (eg, compression and CDT) is often effective.[1]
• Stage II (spontaneously irreversible lymphedema)

  • Edema persists despite elevation and becomes less reversible over time.
  • Fibrotic tissue changes (induration) become apparent.
  • Pitting may be present early but becomes increasingly difficult to elicit as fibrosis advances.
  • Skin changes such as hyperkeratosis and papillomatosis may emerge.
  • Clinicians often describe early vs late stage II based on persistence of pitting and severity of fibrosis, though this is not a formal ISL subdivision.
• Stage III (lymphostatic elephantiasis)

  • Extensive, nonpitting swelling, significant fibrosis, skin thickening, papillomatosis, and deep cutaneous folds are common (see Image. Stage 3 Lymphedema of the Bilateral Lower Extremities).
  • Functional impairment and recurrent infections (eg, cellulitis) are also common.
  • This typically occurs in long-standing, untreated cases like advanced filarial lymphedema.

ISL 2020 Severity Grading by Limb Volume

In addition to clinical staging, the ISL recommends grading severity based on the limb volume difference relative to the contralateral normal limb.[50][79]

• Mild: >5% to <20% volume increase
• Moderate: 20% to 40% volume increase
• Severe: >40% volume increase

The ISL staging system is endorsed by the American Physical Therapy Association (APTA) and the American Venous Forum (AVF) and remains the clinical standard for evaluating and managing lymphedema.[4][80][81]

Prognosis

Lymphedema is a chronic condition with variable outcomes, influenced by its cause, diagnostic severity, and adherence to therapy. Early-stage disease, particularly ISL stage 0 or I, responds well to timely intervention, including CDT, compression, and risk reduction strategies.[58] In contrast, advanced stages with fibrofatty tissue changes are more resistant to reversal and often result in lasting pain, functional decline, and infection risk.[2][82]

Cancer-related lymphedema carries a lifelong risk and may emerge years after oncologic treatment. While not curable, consistent use of compression garments, guided physical therapy, and, when appropriate, surgical interventions can help stabilize symptoms and prevent deterioration.[61][83] Head and neck lymphedema may improve with therapy, but often persists and impacts speech, swallowing, and appearance. If left untreated, lymphedema can lead to recurrent cellulitis, progressive fibrosis, and significant psychosocial burden. However, early identification, patient participation in care, and multidisciplinary coordination are associated with better long-term function and reduced complications.[58]

Individuals with lymphatic and complex vascular malformations commonly exhibit peripheral lymphedema as a key clinical feature. Treatment has increasingly advanced into the molecular field, with mechanistic target of rapamycin inhibitors employed to stabilize and improve vascular abnormalities. Furthermore, results from emerging studies suggest that targeted small-molecule agents that modulate specific cellular pathways may provide effective new therapies for these patients.

Complications

Lymphedema is associated with multiple medical and psychosocial complications:

• Cellulitis and erysipelas

  • Recurrent infections are common and may worsen lymphatic damage.
• Lymphangitis and lymphangioadenitis

  • Inflammation of lymphatic vessels and nodes often follows infection.
• Superficial infections

  • Fungal (eg, intertrigo, dermatophytosis) and bacterial skin infections are frequent.
• Deep vein thrombosis

  • This may occur due to immobility or be confused with lymphedema.
• Functional impairment

  • Chronic swelling limits mobility and daily activities.
• Psychosocial effects

  • Depression, anxiety, and body image issues are prevalent.
• Cosmetic disfigurement

  • Progressive fibroadipose changes cause visible deformity.
• Lymphangiosarcoma

  • A rare, aggressive malignancy that can be found in chronic, untreated cases.
• Amputation

  • This is rarely required for intractable infection or malignant transformation.

Postsurgical complications include partial wound separation, seroma, hematoma, skin necrosis, lymphatic leaks, and infection—especially in irradiated or high-risk tissue beds.

Consultations

The following consultations may be needed:

• Oncology: For cancer-related lymphedema or suspected recurrence.
• Infectious disease: For recurrent cellulitis or complex infections.
• Certified lymphedema therapist: For comprehensive rehabilitation, including manual drainage and compression.
• Vascular or plastic surgery: For surgical candidates (eg, LVA, VLNT, liposuction).
• Dermatology: For chronic skin changes or suspected lymphangiosarcoma.
• Mental health: For psychological support related to disfigurement or disability.

Deterrence and Patient Education

Lymphedema is swelling that can occur after cancer treatment, particularly when lymph nodes have been removed or treated with radiation. Risk increases with lymph node surgery or radiation, infections or injuries, excess body weight, and lack of movement. To help lower risk, patients should begin gentle activity about a week after surgery (if their clinician approves), a healthy weight should be maintained, and their skin should be protected by keeping it clean and moisturized while avoiding cuts, bites, and burns. Compression sleeves or stockings should be recommended (if the care team approves), and pressure or injury to the affected area should be prevented by steering clear of tight clothing, blood draws, or blood pressure cuffs on that side.

Patients should limit heat exposure by avoiding hot tubs and saunas and practicing self-care, such as learning simple massage techniques or using virtual rehabilitation resources when available. They should also watch closely for early signs, such as swelling, a feeling of heaviness or tightness, or clothes and rings becoming tighter on one side, and should contact their care team promptly if these occur. If swelling begins, early treatment is most effective and may include compression garments, special exercises, gentle massage, and complete care by a trained therapist.

Effective long-term lymphedema management relies heavily on patient education and consistent self-care. Patients should learn simplified MLD (eg, self-MLD) techniques to maintain lymph flow during the maintenance phase and practice meticulous infection prevention through careful skin care, hygiene, regular moisturization, and prompt cellulitis treatment.[84] Regular aerobic and resistance exercise, ideally under professional guidance, helps improve lymphatic return and overall function without worsening lymphedema.

Because obesity is a modifiable risk factor, weight loss can improve outcomes and reduce limb volume. Proper use of compression garments is another key management component; patients should be trained in the correct application, removal, and care of compression garments or wraps to ensure consistent use. Preventive measures to avoid limb constriction include avoiding tight clothing or jewelry and blood draws or blood pressure measurements on the affected side.

Psychosocial support is also essential, as patients often face body image issues, anxiety, and the ongoing burden of chronic care. Peer support groups, national lymphedema networks, and standardized educational materials can help patients cope and remain engaged in their care. However, recent analyses show that online patient education materials, including short-form videos on social media, vary widely in quality, accuracy, and readability, highlighting the need for reliable, patient-centered content. Lymphedema patients report higher rates of depression and lower quality of life compared with those who have lipedema, underscoring the significant psychosocial impact of chronic lymphatic dysfunction. In addition, the financial burden—such as the cost of compression garments and therapy—can limit adherence, particularly in lower-resource settings.[71][85]

Enhancing Healthcare Team Outcomes

Effective lymphedema care requires a coordinated, multidisciplinary strategy in which clinicians, nurses, therapists, pharmacists, and mental health professionals collaborate to deliver patient-centered, evidence-based management. A strong interprofessional approach improves outcomes by addressing care's physical, psychological, and educational aspects.[72] Primary care clinicians are key in early recognition, patient education, and timely referral to lymphedema specialists.[71][73] Surgeons and oncologists implement preventive measures during cancer treatment—such as minimally invasive lymph node staging and, when appropriate, immediate lymphaticovenous anastomosis—and refer high-risk individuals for surveillance. Certified lymphedema therapists provide complete decongestive therapy, fit compression garments, and train patients in self-management techniques.

At the same time, nurses and wound care specialists manage skin integrity problems (including lymphorrhea and ulcers), monitor for infections, and reinforce education on meticulous skin care.[86] Physical and occupational therapists focus on improving limb function and range of motion and developing adaptive strategies to support daily activities and return to work. Pharmacists counsel on medications that may influence edema, assist with antibiotic prophylaxis plans when indicated, and encourage adherence to compression therapy. Mental health professionals address depression, anxiety, and self-image concerns related to lymphedema and provide counseling or therapy as needed.

Across these disciplines, clear communication and structured care coordination are critical to enhancing patient safety and outcomes. Clinicians guide diagnosis and long-term treatment planning; nurses and therapists ensure patients understand and can implement skin care, exercise, and compression strategies; and pharmacists and mental health professionals support medical and psychosocial aspects of care. Regular interprofessional meetings, shared electronic health records, and standardized handoff protocols help the team recognize complications, such as infections or worsening edema, early and respond promptly. This collaborative model fosters patient engagement, supports adherence to self-management, and integrates education and psychosocial support, thereby improving quality of life, reducing complications, and strengthening overall team performance in lymphedema management.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Brouillard P, Witte MH, Erickson RP, Damstra RJ, Becker C, Quéré I, Vikkula M. Primary lymphoedema. Nat Rev Dis Primers. 2021 Oct 21;7(1):77. [PubMed: 34675250]

2.

Grada AA, Phillips TJ. Lymphedema: Pathophysiology and clinical manifestations. J Am Acad Dermatol. 2017 Dec;77(6):1009-1020. [PubMed: 29132848]

3.

Manrique OJ, Bustos SS, Ciudad P, Adabi K, Chen WF, Forte AJ, Cheville AL, Jakub JW, McLaughlin SA, Chen HC. Overview of Lymphedema for Physicians and Other Clinicians: A Review of Fundamental Concepts. Mayo Clin Proc. 2022 Oct;97(10):1920-1935. [PubMed: 32829905]

4.

Lurie F, Malgor RD, Carman T, Dean SM, Iafrati MD, Khilnani NM, Labropoulos N, Maldonado TS, Mortimer P, O'Donnell TF, Raffetto JD, Rockson SG, Gasparis AP. The American Venous Forum, American Vein and Lymphatic Society and the Society for Vascular Medicine expert opinion consensus on lymphedema diagnosis and treatment. Phlebology. 2022 May;37(4):252-266. [PMC free article: PMC9069652] [PubMed: 35258350]

5.

Lee SO, Kim IK. Molecular pathophysiology of secondary lymphedema. Front Cell Dev Biol. 2024;12:1363811. [PMC free article: PMC11264244] [PubMed: 39045461]

6.

Ikomi C, Blatt J, Ghofrani S, Zhang R, Ross J, Law JR. Lymphedema in Turner syndrome: correlations with phenotype and karyotype. J Pediatr Endocrinol Metab. 2024 Sep 25;37(9):789-795. [PubMed: 39113198]

7.

Zhang R, Zhang J, Rao L, Chen Z, Wang M. Recurrent pericardial effusion due to Hennekam lymphangiectasia-lymphedema syndrome: a case report and literature review. BMC Cardiovasc Disord. 2025 May 21;25(1):389. [PMC free article: PMC12093679] [PubMed: 40394495]

8.

Letellier ME, Ibrahim M, Towers A, Chaput G. Incidence of lymphedema related to various cancers. Med Oncol. 2024 Sep 17;41(10):245. [PMC free article: PMC11408551] [PubMed: 39289260]

9.

Bernas M, Al-Ghadban S, Thiadens SRJ, Ashforth K, Lin WC, Safa B, Buntic R, Paukshto M, Rovnaya A, McNeely ML. Etiology and treatment of cancer-related secondary lymphedema. Clin Exp Metastasis. 2024 Aug;41(4):525-548. [PubMed: 37777696]

10.

Fu MR, Liu B, Qiu JM, Sun Y, Axelrod D, Guth A, Korth S, Kremer HL, Wang Y. The Effects of Daily-Living Risks on Breast Cancer-Related Lymphedema. Ann Surg Oncol. 2024 Nov;31(12):8076-8085. [PMC free article: PMC11466982] [PubMed: 39090498]

11.

Obeng-Gyasi B, Gokun Y, Elsaid MI, Chen JC, Andersen BL, Carson WE, Jhawar S, Anampa JD, Quiroga D, Skoracki R, Obeng-Gyasi S. The association between allostatic load and lymphedema in breast cancer survivors. Support Care Cancer. 2025 Mar 21;33(4):311. [PMC free article: PMC11928421] [PubMed: 40116971]

12.

Brunelle CL, Serig A. Is axillary web syndrome a risk factor for breast cancer-related lymphedema of the upper extremity? A systematic review and meta-analysis. Breast Cancer Res Treat. 2024 Dec;208(3):471-490. [PubMed: 39414730]

13.

Rockson SG. The unique biology of lymphatic edema. Lymphat Res Biol. 2009;7(2):97-100. [PubMed: 19522679]

14.

Moffatt CJ, Gaskin R, Sykorova M, Dring E, Aubeeluck A, Franks PJ, Windrum P, Mercier G, Pinnington L, Quere I. Prevalence and Risk Factors for Chronic Edema in U.K. Community Nursing Services. Lymphat Res Biol. 2019 Apr;17(2):147-154. [PMC free article: PMC6639109] [PubMed: 30995181]

15.

Deng J, Dietrich MS, Niermann KJ, Sinard RJ, Cmelak AJ, Ridner SH, Gilbert J, Murphy BA. Refinement and Validation of the Head and Neck Lymphedema and Fibrosis Symptom Inventory. Int J Radiat Oncol Biol Phys. 2021 Mar 01;109(3):747-755. [PMC free article: PMC9059777] [PubMed: 33068688]

16.

Kim DJ, Kim DS, Yu Y, Chung JH, Yoon ES. Cross-sectional analysis for lymphedema epidemiology in South Korea by HIRA data: An observational study. Medicine (Baltimore). 2024 Jul 05;103(27):e38779. [PMC free article: PMC11224808] [PubMed: 38968506]

17.

Sharifi N, Ahmad S. Breast cancer-related lymphedema: A critical review on recent progress. Surg Oncol. 2024 Oct;56:102124. [PubMed: 39208532]

18.

Will PA, Kilian K, Bieback K, Fricke F, Berner JE, Kneser U, Hirche C. Lymphedema-Associated Fibroblasts Are Related to Fibrosis and Stage Progression in Patients and a Murine Microsurgical Model. Plast Reconstr Surg. 2024 Oct 01;154(4):688e-700e. [PubMed: 37832143]

19.

Erdoğan İyigün Z, Ozmen T, İlgün S, Nakipoğlu C, Özkurt E, Çelebi F, Ünal Ç, Öztürk A, Alço G, Ordu Ç, Soybir G. Evaluation of Long-Term Lymphedema Rate in Patients With Subclinical Lymphedema Diagnosed in the Preoperative Period via Bioimpedance. Eur J Breast Health. 2025 Jan 01;21(1):40-45. [PMC free article: PMC11706125] [PubMed: 39744892]

20.

Shamsesfandabadi P, Shams Esfand Abadi M, Yin Y, Carpenter DJ, Peluso C, Hilton C, Coopey SB, Gomez J, Beriwal S, Champ CE. Resistance Training and Lymphedema in Breast Cancer Survivors. JAMA Netw Open. 2025 Jun 02;8(6):e2514765. [PMC free article: PMC12159776] [PubMed: 40498485]

21.

Demirci M, Şanal C. Evaluation of the Treatment Process with Home Exercise Program and Telerehabilitation in Patients with Breast Cancer-Related Lymphedema: A Case-Control Study. Lymphat Res Biol. 2025 Jun;23(3):169-177. [PubMed: 39866130]

22.

Hao K, Sun Y, Zhu Y, Xin J, Zhang L, Li B, Shen W. A retrospective analysis of Stewart-Treves syndrome in the context of chronic lymphedema. An Bras Dermatol. 2023 May-Jun;98(3):287-295. [PMC free article: PMC10173066] [PubMed: 36746732]

23.

Yoshimatsu Y, Watabe T. Emerging roles of inflammation-mediated endothelial-mesenchymal transition in health and disease. Inflamm Regen. 2022 Feb 07;42(1):9. [PMC free article: PMC8818500] [PubMed: 35130955]

24.

Podder PS, Bhadra D, Pal S, Klimberg VS, Stolarz AJ. Clinical Relevance of Animal Models of Lymphatic Dysfunction and Lymphedema. Microcirculation. 2025 May;32(4):e70009. [PMC free article: PMC12096149] [PubMed: 40400414]

25.

Campbell AC, Baik JE, Sarker A, Brown S, Park HJ, Kuonqui KG, Shin J, Pollack BL, Roberts A, Ashokan G, Rubin J, Kataru RP, Dayan JH, Barrio AV, Mehrara BJ. Breast Cancer-Related Lymphedema Results in Impaired Epidermal Differentiation and Tight Junction Dysfunction. J Invest Dermatol. 2025 Jan;145(1):85-97.e4. [PMC free article: PMC12043072] [PubMed: 38879154]

26.

Hahn BA, Kleeven A, Richir MC, Witkamp AJ, Kuijpers AMJ, de Jong T, Qiu S, Coert JH, Krijgh DD. Objectifying Clinical Outcomes After Lymphaticovenous Anastomosis and Vascularized Lymph Node Transfer in the Treatment of Extremity Lymphedema: A Systematic Review and Meta-Analysis. Microsurgery. 2025 Mar;45(3):e70050. [PMC free article: PMC11895410] [PubMed: 40066947]

27.

Gucciardo F, Lebeau A, Pirson S, Buntinx F, Ivanova E, Blacher S, Brouillard P, Deroye J, Baudin L, Pirnay A, Morfoisse F, Villette C, Nizet C, Lallemand F, Munaut C, Alitalo K, Geris L, Vikkula M, Gautier-Isola M, Noel A. Targeting uPARAP Modifies Lymphatic Vessel Architecture and Attenuates Lymphedema. Circulation. 2025 May 13;151(19):1412-1429. [PMC free article: PMC12063686] [PubMed: 40035133]

28.

Rannikko EH, Pajula S, Suominen SH, Kiiski J, Mani MR, Halle M, Kaartinen IS, Lahdenperä O, Arnardottir TH, Kauhanen SM, Kavola H, Majava M, Niemi TS, Brück NM, Mäki MT, Seppänen MP, Saarikko AM, Hartiala P. Phase II Study Shows the Effect of Adenoviral Vascular Endothelial Growth Factor C and Lymph Node Transfer in Lymphedema. Plast Reconstr Surg. 2025 Feb 01;155(2):256e-267e. [PubMed: 39137430]

29.

Mortada H, Alhithlool AW, AlBattal NZ, Shetty RK, Al-Mekhlafi GA, Hong JP, Alshomer F. Lipedema: Clinical Features, Diagnosis, and Management. Arch Plast Surg. 2025 May;52(3):185-196. [PMC free article: PMC12081092] [PubMed: 40386000]

30.

Kamamoto F, Baiocchi JMT, Batista BN, Ribeiro RDA, Modena DAO, Gornati VC. Lipedema: exploring pathophysiology and treatment strategies - state of the art. J Vasc Bras. 2024;23:e20240025. [PMC free article: PMC11758576] [PubMed: 39866170]

31.

Bowman C, Rockson SG. The Role of Inflammation in Lymphedema: A Narrative Review of Pathogenesis and Opportunities for Therapeutic Intervention. Int J Mol Sci. 2024 Mar 31;25(7) [PMC free article: PMC11011271] [PubMed: 38612716]

32.

Wolf S, von Atzigen J, Kaiser B, Grünherz L, Kim BS, Giovanoli P, Lindenblatt N, Gousopoulos E. Is Lymphedema a Systemic Disease? A Paired Molecular and Histological Analysis of the Affected and Unaffected Tissue in Lymphedema Patients. Biomolecules. 2022 Nov 11;12(11) [PMC free article: PMC9687735] [PubMed: 36421681]

33.

Sung C, Wang S, Hsu J, Yu R, Wong AK. Current Understanding of Pathological Mechanisms of Lymphedema. Adv Wound Care (New Rochelle). 2022 Jul;11(7):361-373. [PMC free article: PMC9051876] [PubMed: 34521256]

34.

García Nores GD, Ly CL, Cuzzone DA, Kataru RP, Hespe GE, Torrisi JS, Huang JJ, Gardenier JC, Savetsky IL, Nitti MD, Yu JZ, Rehal S, Mehrara BJ. CD4⁺ T cells are activated in regional lymph nodes and migrate to skin to initiate lymphedema. Nat Commun. 2018 May 17;9(1):1970. [PMC free article: PMC5958132] [PubMed: 29773802]

35.

Baik JE, Park HJ, Kataru RP, Savetsky IL, Ly CL, Shin J, Encarnacion EM, Cavali MR, Klang MG, Riedel E, Coriddi M, Dayan JH, Mehrara BJ. TGF-β1 mediates pathologic changes of secondary lymphedema by promoting fibrosis and inflammation. Clin Transl Med. 2022 Jun;12(6):e758. [PMC free article: PMC9160979] [PubMed: 35652284]

36.

Pirri C, Ferraretto C, Pirri N, Bonaldo L, De Caro R, Masiero S, Stecco C. Ultrasound Examination of Skin, Fasciae and Subcutaneous Tissue: Optimizing Rehabilitation for Secondary Upper Limb Lymphedema. Diagnostics (Basel). 2024 Dec 15;14(24) [PMC free article: PMC11674495] [PubMed: 39767185]

37.

Goss JA, Greene AK. Sensitivity and Specificity of the Stemmer Sign for Lymphedema: A Clinical Lymphoscintigraphic Study. Plast Reconstr Surg Glob Open. 2019 Jun;7(6):e2295. [PMC free article: PMC6635205] [PubMed: 31624689]

38.

Vargo M, Aldrich M, Donahue P, Iker E, Koelmeyer L, Crescenzi R, Cheville A. Current diagnostic and quantitative techniques in the field of lymphedema management: a critical review. Med Oncol. 2024 Sep 05;41(10):241. [PMC free article: PMC11377676] [PubMed: 39235664]

39.

Varagur K, Shetty AS, Saoud K, Ochoa E, Skladman R, Skolnick GB, Sacks JM, Christensen JM. Association between Bioimpedance Spectroscopy and Magnetic Resonance Lymphangiography in the Diagnosis and Assessment of Lymphedema. J Reconstr Microsurg. 2024 Mar;40(3):177-185. [PubMed: 37236242]

40.

Ridner SH, Dietrich MS, Spotanski K, Doersam JK, Cowher MS, Taback B, McLaughlin S, Ajkay N, Boyages J, Koelmeyer L, DeSnyder S, Shah C, Vicini F. A Prospective Study of L-Dex Values in Breast Cancer Patients Pretreatment and Through 12 Months Postoperatively. Lymphat Res Biol. 2018 Oct;16(5):435-441. [PMC free article: PMC6913109] [PubMed: 30130147]

41.

Ridner SH, Dietrich MS, Boyages J, Koelmeyer L, Elder E, Hughes TM, French J, Ngui N, Hsu J, Abramson VG, Moore A, Shah C. A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention. Lymphat Res Biol. 2022 Dec;20(6):618-628. [PMC free article: PMC9810346] [PubMed: 35099283]

42.

Shah C, Whitworth P, Valente S, Schwarz GS, Kruse M, Kohli M, Brownson K, Lawson L, Dupree B, Vicini FA. Bioimpedance spectroscopy for breast cancer-related lymphedema assessment: clinical practice guidelines. Breast Cancer Res Treat. 2023 Feb;198(1):1-9. [PMC free article: PMC9883343] [PubMed: 36566297]

43.

Turgay T, Denkçeken T, Maralcan G. The role of bioimpedance spectroscopy method in severity and stages of breast cancer-related lymphedema. Turk J Surg. 2022 Mar;38(1):11-17. [PMC free article: PMC9278353] [PubMed: 35873745]

44.

Borman P, Yaman A, Doğan L, Arıkan Dönmez A, Koyuncu EG, Balcan A, Aksoy S, Özaslan C, Akın R, Üneş K. The Comparative Frequency of Breast Cancer-Related Lymphedema Determined by Bioimpedance Spectroscopy and Circumferential Measurements. Eur J Breast Health. 2022 Apr;18(2):148-154. [PMC free article: PMC8987859] [PubMed: 35445173]

45.

Nagy BI, Mohos B, Tzou CJ. Imaging Modalities for Evaluating Lymphedema. Medicina (Kaunas). 2023 Nov 16;59(11) [PMC free article: PMC10673374] [PubMed: 38004065]

46.

Brezgyte G, Mills M, van Zanten M, Gordon K, Mortimer PS, Ostergaard P. A systematic review of indocyanine green lymphography imaging for the diagnosis of primary lymphoedema. Br J Radiol. 2025 Apr 01;98(1168):517-526. [PMC free article: PMC11919075] [PubMed: 39836641]

47.

Mo YW, Lee SJ, Lee DW, Lee WJ, Im SH, Suh YC. Contrast-enhanced ultrasonography as an adjunctive method to ICG lymphography for functional lymphaticovenous anastomosis. J Surg Oncol. 2024 Apr;129(5):965-974. [PubMed: 38221666]

48.

Abdelfattah U, Elbanoby T, Omarah M, Abdelmaksoud SM, Allam E, Monir S. LVA for Advanced Unilateral Lower Extremity Lymphedema: Impact of ICG Lymphography of Normal Side in Improving the Lymphatic Detection Rate and Operative Time. Arch Plast Surg. 2025 May;52(3):178-184. [PMC free article: PMC12081089] [PubMed: 40385998]

49.

Arends CR, Van Aperen K, van der Molen L, van den Brekel MWM, Stuiver MM. Limited consensus on the diagnosis and treatment of lymphedema after head and neck cancer: results from an International Delphi study. Disabil Rehabil. 2025 Mar;47(5):1234-1242. [PubMed: 38874330]

50.

Torgbenu E, Luckett T, Buhagiar MA, Phillips JL. Guidelines Relevant to Diagnosis, Assessment, and Management of Lymphedema: A Systematic Review. Adv Wound Care (New Rochelle). 2023 Jan;12(1):15-27. [PubMed: 35196892]

51.

Borman P, Yaman A, Yasrebi S, Pınar İnanlı A, Arıkan Dönmez A. Combined Complete Decongestive Therapy Reduces Volume and Improves Quality of Life and Functional Status in Patients With Breast Cancer-Related Lymphedema. Clin Breast Cancer. 2022 Apr;22(3):e270-e277. [PubMed: 34535391]

52.

Shamoun S, Ahmad M. Complete Decongestive Therapy Effect on Breast Cancer Related to Lymphedema: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. Asian Pac J Cancer Prev. 2023 Jul 01;24(7):2225-2238. [PMC free article: PMC10676504] [PubMed: 37505751]

53.

Bergmann A, Andrade MFC, Dias M. Comments to "The Randomized Controlled Study of Low-Level Laser Therapy, Kinesio-Taping and Manual Lymphatic Drainage in Patients With Stage II Breast Cancer-Related Lymphedema". Eur J Breast Health. 2023 Apr;19(2):184-185. [PMC free article: PMC10071891] [PubMed: 37025573]

54.

Gilchrist L, Levenhagen K, Davies CC, Koehler L. Effectiveness of complete decongestive therapy for upper extremity breast cancer-related lymphedema: a review of systematic reviews. Med Oncol. 2024 Oct 23;41(11):297. [PMC free article: PMC11496316] [PubMed: 39438358]

55.

DiCecco S, Davies CC, Gilchrist L, Levenhagen K, Letellier ME, Rivera A, Weiss J, Klose G, Hodgkins L, Anderson E, Cheville A, Moore K, Koehler L. Complete decongestive therapy phase 1: an expert consensus document. Med Oncol. 2024 Nov 02;41(12):304. [PubMed: 39487245]

56.

Gultekin SC, Karadibak D, Cakir AB, Guc ZG, Yavuzsen T. Self-administered versus lymphedema therapist-administered complex decongestive therapy protocol in breast cancer-related lymphedema: a non-inferiority randomized controlled trial with three-month follow-up. Breast Cancer Res Treat. 2025 Jul;212(1):123-138. [PMC free article: PMC12086114] [PubMed: 40329151]

57.

Reisshauer A, Tsatrafilis E, Kornappel S, Huscher D, Liebl ME. A randomized, controlled noninferiority study of adjustable compression wraps compared with inelastic multilayer bandaging used in the intensive complex decongestive therapy of lower leg lymphedema. J Vasc Surg Venous Lymphat Disord. 2025 Jul;13(4):102214. [PMC free article: PMC11995056] [PubMed: 40015477]

58.

Dzupina A, Yaluri N, Singh J, Jankajova M. Predictors of the Efficacy of Lymphedema Decongestive Therapy. Medicina (Kaunas). 2025 Jan 27;61(2) [PMC free article: PMC11857323] [PubMed: 40005348]

59.

Deng C, Wu Z, Cai Z, Zheng X, Tang C. Conservative medical intervention as a complement to CDT for BCRL therapy: a systematic review and meta-analysis of randomized controlled trials. Front Oncol. 2024;14:1361128. [PMC free article: PMC11082302] [PubMed: 38737896]

60.

Davies C, Levenhagen K, Ryans K, Perdomo M, Gilchrist L. Interventions for Breast Cancer-Related Lymphedema: Clinical Practice Guideline From the Academy of Oncologic Physical Therapy of APTA. Phys Ther. 2020 Jul 19;100(7):1163-1179. [PMC free article: PMC7412854] [PubMed: 32589208]

61.

de-la-Cruz-Fernández L, Galiano-Castillo N, Galván-Banqueri P, Castro-Martín E, Lozano-Lozano M, Postigo-Martin P, Lopez-Garzon M. Lymphedema management in patients with head and neck cancer: a systematic review of randomized controlled trials on physical therapy interventions. Support Care Cancer. 2025 Apr 26;33(5):420. [PMC free article: PMC12033101] [PubMed: 40285885]

62.

Wang L, Liu Y, Zhang W, Wang Y, Zhai Z, Cheng H, Yao N. Effects of resistance training on breast cancer-related arm lymphedema: a systematic review and dose-response meta-analysis. Support Care Cancer. 2025 Apr 17;33(5):395. [PubMed: 40244422]

63.

Yakaback S, Bains I, Temple-Oberle C. A promising step forward: early results from a randomized clinical trial support the efficacy of immediate lymphatic reconstruction following axillary lymph node dissection. Gland Surg. 2024 Apr 29;13(4):596-599. [PMC free article: PMC11074665] [PubMed: 38720670]

64.

Hassan AM, Hajj JP, Lewis JP, Ahmed S, Fisher CS, Ludwig KK, Danforth RM, VonDerHaar RJ, Bamba R, Lester ME, Hassanein AH. Long-Term Outcomes of Lymphedema After Immediate Lymphatic Reconstruction Following Axillary Lymph Node Dissection. Ann Surg Oncol. 2025 Aug;32(8):5817-5826. [PMC free article: PMC12222251] [PubMed: 40238065]

65.

Levy AS, Murphy AI, Ishtihar S, Peysakhovich A, Taback B, Grant RT, Ascherman JA, Feldman S, Rohde CH. Lymphatic Microsurgical Preventive Healing Approach for the Primary Prevention of Lymphedema: A 4-Year Follow-Up. Plast Reconstr Surg. 2023 Feb 01;151(2):413-420. [PubMed: 36696330]

66.

Agarwal S, Garza RM, Chang DW. Lymphatic Microsurgical Preventive Healing Approach (LYMPHA) for the prevention of secondary lymphedema. Breast J. 2020 Apr;26(4):721-724. [PubMed: 31631442]

67.

Kappos EA, Haas Y, Schulz A, Peters F, Savanthrapadian S, Stoffel J, Katapodi MC, Mucklow R, Kaiser B, Haumer A, Etter S, Cattaneo M, Staub D, Ribi K, Shaw J, Handschin TM, Eisenhardt S, Visconti G, Franceschini G, Scardina L, Longo B, Vetter M, Zaman K, Plock JA, Scaglioni M, Gonzalez EG, Quildrian SD, Felmerer G, Mehrara BJ, Ayala JM, Pons G, Kalbermatten DF, Sacks JM, Halle M, Muntean MV, Taylor EM, Mani M, Jung FJ, di Summa PG, Demiri E, Dionyssiou D, Groth AK, Heine N, Vorstenborsch J, Isaac KV, Qiu SS, Engels PE, Serre A, Eberhardt AL, Ebner S, Schwenkglenks M, Stoel Y, Leo C, Horch RE, Blondeel P, Behr B, Kneser U, Prantl L, Boll DT, Granziera C, Hemkens L, Lindenblatt N, Haug M, Schaefer DJ, Hirche C, Pusic AL, Seidenstuecker K, Harder Y, Weber W. The LYMPH trial: comparing microsurgical with conservative treatment for chronic breast cancer-associated lymphoedema - study protocol of a pragmatic randomised international multicentre superiority trial. BMJ Open. 2025 Feb 17;15(2):e090662. [PMC free article: PMC11836839] [PubMed: 39961719]

68.

Pirincci CS, Mete O, Yasa ME, Dalyan M. A comparative evaluation of the efficacy of complete decongestive therapy in the treatment of unilateral breast cancer-related lymphedema with and without metabolic syndrome. Support Care Cancer. 2024 Jun 29;32(7):473. [PMC free article: PMC11217042] [PubMed: 38949715]

69.

Copeland-Halperin LR, Hyland CJ, Gadiraju GK, Xiang DH, Bellon JR, Lynce F, Dey T, Troll EP, Ryan SJ, Nakhlis F, Broyles JM. Preoperative Risk Factors for Lymphedema in Inflammatory Breast Cancer. J Reconstr Microsurg. 2024 May;40(4):311-317. [PubMed: 37751880]

70.

Coriddi M, Dayan J, Bloomfield E, McGrath L, Diwan R, Monge J, Gutierrez J, Brown S, Boe L, Mehrara B. Efficacy of Immediate Lymphatic Reconstruction to Decrease Incidence of Breast Cancer-related Lymphedema: Preliminary Results of Randomized Controlled Trial. Ann Surg. 2023 Oct 01;278(4):630-637. [PMC free article: PMC10527595] [PubMed: 37314177]

71.

Wang Y, Tong L, Wang S, Shi W, Xu D. Effectiveness of a lymphedema prevention program for patients with breast cancer: A randomized controlled trial based on the Protection Motivation Theory and Information-Motivation-Behavioral Skills Model. Asia Pac J Oncol Nurs. 2025 Dec;12:100667. [PMC free article: PMC11926721] [PubMed: 40124658]

72.

Li Q, Yan Y, Luo Y, Chen X. Knowledge, belief, and practice in prevention of lymphedema in postoperative breast cancer patients and analysis of associated factors. Front Public Health. 2025;13:1474419. [PMC free article: PMC12171371] [PubMed: 40529695]

73.

Whitworth P, Vicini F, Valente SA, Brownson K, DuPree B, Kohli M, Lawson L, Shah C. Reducing rates of chronic breast cancer-related lymphedema with screening and early intervention: an update of recent data. J Cancer Surviv. 2024 Apr;18(2):344-351. [PubMed: 35947288]

74.

Duhon BH, Phan TT, Taylor SL, Crescenzi RL, Rutkowski JM. Current Mechanistic Understandings of Lymphedema and Lipedema: Tales of Fluid, Fat, and Fibrosis. Int J Mol Sci. 2022 Jun 14;23(12) [PMC free article: PMC9223758] [PubMed: 35743063]

75.

Lomeli LD, Makin V, Bartholomew JR, Burguera B. Lymphedema vs lipedema: Similar but different. Cleve Clin J Med. 2024 Jul 01;91(7):425-436. [PubMed: 38950986]

76.

van la Parra RFD, Deconinck C, Pirson G, Servaes M, Fosseprez P. Lipedema: What we don't know. J Plast Reconstr Aesthet Surg. 2023 Sep;84:302-312. [PubMed: 37390539]

77.

Myung Y, Park S, Kim BR, Yang EJ, Park JK, Kang Y. Validation of a Lymphedema Index Score Based on Noncontrast Magnetic Resonance Lymphangiography: Correlation with Clinical Staging and Indocyanine Green Lymphangiography. Lymphat Res Biol. 2023 Feb;21(1):70-77. [PubMed: 35501954]

78.

Sakai H, Miyazaki T. Need for better protocol and severity staging system of indocyanine green lymphography. J Plast Reconstr Aesthet Surg. 2023 Apr;79:19-20. [PubMed: 36841144]

79.

Li Q, Tang Q, Luo K, Zhang S, Zhou X, Yang Y, Li P, Qi J, Zhang Y. Comparative analysis of the International Society of Lymphology and Taiwan Lymphoscintigraphy Staging systems: correlation, reliability, and a quantitative severity index in extremity lymphedema. Quant Imaging Med Surg. 2025 Mar 03;15(3):1822-1833. [PMC free article: PMC11948426] [PubMed: 40160668]

80.

Executive Committee of the International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema: 2020 Consensus Document of the International Society of Lymphology. Lymphology. 2020;53(1):3-19. [PubMed: 32521126]

81.

Guo J, Li X, Liu M, Shen W, Yue Y, Wang R. The value of nonenhanced magnetic resonance imaging in the grading of primary lower extremity lymphedema. J Vasc Surg Venous Lymphat Disord. 2025 May;13(3):102168. [PMC free article: PMC11872591] [PubMed: 39826874]

82.

Rockson SG, Keeley V, Kilbreath S, Szuba A, Towers A. Cancer-associated secondary lymphoedema. Nat Rev Dis Primers. 2019 Mar 28;5(1):22. [PubMed: 30923312]

83.

Kavak SK, Ünver G. Effect of complex decongestive therapy on frailty and quality of life in women with breast cancer-related lymphedema: the before-and-after treatment study. Front Oncol. 2024;14:1297074. [PMC free article: PMC11157059] [PubMed: 38854727]

84.

Cansız G, Arıkan Dönmez A, Kapucu S, Borman P. The effect of a self-management lymphedema education program on lymphedema, lymphedema-related symptoms, patient compliance, daily living activities and patient activation in patients with breast cancer-related lymphedema: A quasi-experimental study. Eur J Oncol Nurs. 2022 Feb;56:102081. [PubMed: 34875398]

85.

Karaca-Mandic P, Solid CA, Armer JM, Skoracki R, Campione E, Rockson SG. Lymphedema self-care: economic cost savings and opportunities to improve adherence. Cost Eff Resour Alloc. 2023 Jul 29;21(1):47. [PMC free article: PMC10386258] [PubMed: 37516870]

86.

Hemati M, Rivaz M, Khademian Z. Lymphedema self-management mobile application with nurse support for post breast cancer surgery survivors: description of the design process and prototype evaluation. BMC Cancer. 2024 Aug 08;24(1):973. [PMC free article: PMC11308577] [PubMed: 39118042]

Disclosure: Bala Nimmana declares no relevant financial relationships with ineligible companies.

Disclosure: Ali Kimyaghalam declares no relevant financial relationships with ineligible companies.

Disclosure: Biagio Manna declares no relevant financial relationships with ineligible companies.